Here are three things to know.
1. Lucemyra (lofexidine hydrochloride) may lessen the severity of opioid withdrawal symptoms; it is only approved for treatment for up to 14 days and may not completely prevent withdrawal symptoms.
2. Lucemyra is an oral, selective alpha 2-adrenergic receptor agonist that reduces the release of norepinephrine, which is believed to play a role in many opioid withdrawal symptoms.
3. An independent FDA advisory committee supported approving Lucemyra in March.
The treatment had fast-track designation and was reviewed under the FDA’s priority review process.
More articles on practice management:
The CORE Institute plants roots in new medical campus: 3 takeaways
Orthopedic surgeon Dr. Armin Tehrany now a NYPD police surgeon: 5 things to know
Primary care compensation rose at rate nearly double of specialty: 6 things to note
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
